How to buy Uniqure stock (QURE)

Uniqure is a biotechnology business based in the US. Uniqure shares (QURE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $16.46 – an increase of 9.3% over the previous week. Uniqure employs 480 staff and has a trailing 12-month revenue of around $28.6 million.

Our top picks for where to buy Uniqure stock

Buy Uniqure stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Uniqure stock price (NASDAQ: QURE)

Use our graph to track the performance of QURE stocks over time.

Uniqure shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$16.46
52-week range	$3.73 - $17.39
50-day moving average more info button	$6.39
200-day moving average more info button	$5.83
Wall St. target price	$29.64
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.95

Is it a good time to buy Uniqure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Uniqure price performance over time

Historical closes compared with the close of $17.4 from 2024-12-16

1 week (2024-12-11)	11.18%
1 month (2024-11-19)	198.97%
3 months (2024-09-18)	202.08%
6 months (2024-06-18)	280.74%

1 year (2023-12-18)	118.05%
2 years (2022-12-16)	-24.71%
3 years (2021-12-17)	21.23
5 years (2019-12-18)	70.03

Uniqure financials

Revenue TTM	$28.6 million
Gross profit TTM	$-87,370,000
Return on assets TTM	-16.62%
Return on equity TTM	-147.57%
Profit margin	0%
Book value	$1.15
Market Capitalization more info button	$762.8 million

TTM: trailing 12 months

Uniqure share dividends

We're not expecting Uniqure to pay a dividend over the next 12 months.

Have Uniqure's shares ever split?

Uniqure's shares were split on a 1:5 basis on 30 January 2014 . So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Uniqure shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Uniqure shares which in turn could have impacted Uniqure's share price.

Uniqure share price volatility

Over the last 12 months, Uniqure's shares have ranged in value from as little as $3.73 up to $17.39. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Uniqure's is 0.902. This would suggest that Uniqure's shares are less volatile than average (for this exchange).

Uniqure overview

uniQure N. V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Frequently asked questions

What percentage of Uniqure is owned by insiders or institutions?
Currently 9.226% of Uniqure shares are held by insiders and 81.826% by institutions. How many people work for Uniqure?
Latest data suggests 480 work at Uniqure. When does the fiscal year end for Uniqure?
Uniqure's fiscal year ends in December. Where is Uniqure based?
Uniqure's address is: Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP What is Uniqure's ISIN number?
Uniqure's international securities identification number is: NL0010696654 What is Uniqure's CUSIP number?
Uniqure's Committee on Uniform Securities Identification Procedures number is: N90064101